Here’s the extracted information from the provided visual abstract:
SOURCE
Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus
Study Design:
- A phase 3, multicenter, randomized clinical trial.
Objective:
- To explore the efficacy and safety of Sorafenib plus transarterial chemoembolization (TACE) versus Sorafenib alone as postoperative adjuvant therapy for patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus.
Participants:
- Total: 158 Patients
- Inclusion Criteria:
- Aged 18-75 years
- Primary HCC without any treatments
- Received curative hepatic resection
- ECOG score 0-1
- Child-Pugh grade A
- Sufficient liver and kidney function
- Exclusion Criteria:
- Diffused lesions
- Tumor thrombosis in superior mesenteric vein (SMV) or inferior vena cava (IVC)
- Extra-hepatic metastasis
- Contraindication of TACE
Intervention Groups:
- TACE plus Sorafenib (n = 79)
- Sorafenib alone (n = 79)
Primary Outcome:
- Recurrence-free survival (months)
- Results:
- TACE plus Sorafenib: 16.8 months
- Sorafenib alone: 12.6 months
- Hazard Ratio (HR): 0.57 (95% Confidence Interval (CI): 0.39-0.83; P = 0.002)
Secondary Outcomes:
- Overall survival (months)
- Results:
- TACE plus Sorafenib: 30.4 months
- Sorafenib alone: 22.5 months
- HR: 0.57 (95% CI: 0.39-0.91; P = 0.02)
- Most common grade 3/4 adverse event: Hand-foot syndrome
- Results:
- TACE plus Sorafenib: 29.1%
- Sorafenib alone: 30.4%
Conclusion:
- The combination of sorafenib and transarterial chemoembolization as postoperative adjuvant therapy resulted in longer recurrence-free survival and overall survival than sorafenib alone, and was well tolerated.
Citation:
- Peng Z et al. JAMA Surg 2024. doi:10.1001/jamasurg.2024.0506
This summary captures the key points from the visual abstract, including study design, objectives, participant details, intervention groups, outcomes, and the conclusion.